Synexa Life Sciences has established its position as a leading specialist in clinical biomarker stratification and bioanalysis. For over 20 years, Synexa Life Sciences has supported large and emerging biopharma customers across the globe to achieve their clinical milestones through the delivery of cutting-edge biomarker and bioanalytical services. Synexa specializes in the development, validation and delivery of a wide range of complex and custom-designed assays across five laboratory locations. Synexa Life Sciences’ guiding principles are reflected in our collaborative approach to providing customized, flexible solutions to meet our customers specific needs. We pride ourselves on our scientific know how and our ability to partner with our customers to contribute to the furtherment of scientific development and ultimately better management and treatment of human health. Synexa is a privately held company, backed by Gilde Healthcare, a specialized European healthcare investor. Synexa is led by a growing team of industry experts and highly experienced scientists based across five laboratory locations including Berlin, London, Cape Town, Turku (Finland) and Rockville, Maryland (USA). Priding ourselves as a leading player at the forefront of our industry we have recently acquired Syrinx Bioanalytical group to enhance our offering and provide our customers with a broader range of services, deeper scientific expertise, a wider set of analytical platforms across an expanded geographical footprint. Over the coming years, Synexa aims to continue to grow, both organically and through acquisitions, to ensure we can meet the needs of our expanding customer base while becoming the leading global specialist in biomarker and bioanalytical solutions for the clinical trial industry.